Bank of America keeps USD 8.00 target for Novavax stock

Published on 10/24/2026 at 19:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bank of America keeps its USD 8.00 target on October 23, 2026. Novavax stock costs EUR 8.70 on October 24, 2026 at 1:04 p.m. CEST.

Bank of America keeps USD 8.00 target

Bank of America maintained its Sell rating and USD 8.00 target on October 23, 2026.
Novavax reported USD 56.70 million in second-quarter 2026 revenue and a USD 53.39 million net loss.
Novavax stock costs EUR 8.70 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST.

NVAX, US6700024010, Illustration mit AI erstellt.

Bank of America Securities maintained its Sell rating on Novavax and set an USD 8.00 price target on October 23, 2026, according to Markets Insider. The target remains below the company's latest reported Nasdaq price in USD, keeping the analyst view cautious. Yahoo Finance reported that Novavax's second-quarter 2026 revenue was USD 56.70 million and its net loss was USD 53.00 million. Novavax was trading at EUR 8.70 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST.

Analyst caution meets a lower target

Bank of America analyst Alec Stranahan kept the Sell rating while setting the USD 8.00 target, the October 23, 2026 report said. The target is below the USD 10.75 average price target cited in the same report, although that consensus figure is not a recommendation by the company. The contrast matters because the latest analyst action did not represent a rating upgrade.

Second-quarter figures set the hurdle

Novavax's second-quarter 2026 revenue fell to USD 56.70 million from USD 239.24 million in the second quarter of 2025, while the company moved from a USD 106.51 million profit to a USD 53.39 million GAAP net loss. The comparison was affected by prior-year milestone and amendment revenue, according to the October 23, 2026 Markets Insider report.

The earnings call dated August 6, 2026 also said product sales reached USD 19.00 million in the second quarter of 2026, up 76.00 percent from the prior-year period. Novavax set adjusted total revenue guidance for fiscal year 2026 at USD 235.00 million to USD 275.00 million, with a midpoint of USD 255.00 million.

November results provide the next test

Novavax is scheduled to report third-quarter 2026 results on November 5, 2026, before the U.S. market opens, with an earnings call planned for 8:30 a.m. ET, according to MarketBeat. The published consensus expects USD 74.62 million in revenue and a loss of USD 0.22 per share for that quarter. Those estimates provide a measurable test for whether seasonal vaccine demand can lift revenue from the second-quarter base.

Novavax stock stays tied to execution

The stock's investor case now rests on the gap between analyst caution and the company's partnership-led revenue plan. The second-quarter figures show the scale of the comparison problem, while the fiscal-year guidance and November reporting date offer the next concrete checkpoints.

The further course of trading is shown by the continuously updated real-time quote of Novavax stock.